DNA Vaccine May Protect Against Accumulation of Toxic Amyloid in Alzheimer’s
June 1, 2017
Sangamo’s Research in Alzheimer’s Significantly Reduced Tau Levels in Mice
June 1, 2017
Acadia Investigates Nuplazid (Pimavanserin) Therapy to Treat Psychosis in Alzheimer’s Patients

Acadia Pharmaceuticals plans to start a Phase 3 clinical program to explore the effect of Nuplazid (pimavanserin) in Alzheimer’s disease patients with psychosis. The medication was approved by the U.S. Food and Drug Administration in April 2016 to treat similar problems with Parkinson’s patients.